首页 › 弥漫性大B细胞淋巴瘤 › 得克萨斯州 › Houston
Houston TX 弥漫性大B细胞淋巴瘤临床试验
18项针对 弥漫性大B细胞淋巴瘤的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
招募中3 期
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- MD Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Baylor College of Medicine, Houston
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
招募中观察性研究
- MDA, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
招募中1/2 期
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
招募中2 期
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
招募中观察性研究
- Texas Children's Hospital, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
招募中2 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- University of Texas MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
招募中1 期
- The University of TX MD Anderson Cancer Center, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
招募中1 期
- Md Anderson Cancer Center, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Md Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
招募中1/2 期
- MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- MD Anderson Cancer Center, Houston
其他城市的 弥漫性大B细胞淋巴瘤试验
- New York City, NY20 项研究
- Baldwin Park, CA19 项研究
- Los Angeles, CA18 项研究
- Chicago, IL18 项研究
- Milwaukee, WI17 项研究
- Nashville, TN17 项研究
- Boston, MA17 项研究
- Philadelphia, PA15 项研究
- Durham, NC15 项研究
- Portland, OR15 项研究
- Cleveland, OH13 项研究
- Seattle, WA13 项研究
Houston的其他研究
- 非小细胞肺癌143 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）124 项研究
- 结直肠癌101 项研究
- 转移性癌症100 项研究
- 卵巢癌90 项研究
- 急性髓系白血病88 项研究
- 肺癌78 项研究
- 前列腺癌73 项研究
- 子宫内膜癌69 项研究
- 黑色素瘤61 项研究
- 胰腺癌59 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。